Yipinna announced that in 2025, the relevant meetings of the company deliberated and passed a bill to transfer 15.25% of Arthrosi, a minority shareholder of Guangzhou Ruianbo, a wholly-owned subsidiary, and that Rio Biotech plans to transfer 6.8 million US dollars of its own capital. Recently, Guangzhou Ruianbo completed the registration procedure for the industrial and commercial change. After the change, Ruiao Biotech held 100% of its shares.

Yipinna announced that in 2025, the relevant meetings of the company deliberated and passed a bill to transfer 15.25% of Arthrosi, a minority shareholder of Guangzhou Ruianbo, a wholly-owned subsidiary, and that Rio Biotech plans to transfer 6.8 million US dollars of its own capital. Recently, Guangzhou Ruianbo completed the registration procedure for the industrial and commercial change. After the change, Ruiao Biotech held 100% of its shares.